A systematic review of treatments for refractory depression in older people
- PMID: 21454919
- DOI: 10.1176/appi.ajp.2011.10081165
A systematic review of treatments for refractory depression in older people
Abstract
Objective: The authors systematically reviewed the management of treatment-refractory depression in older people (defined as age 55 or older).
Method: The authors conducted an electronic database search and reviewed the 14 articles that fit predetermined criteria. Refractory depression was defined as failure to respond to at least one course of treatment for depression during the current illness episode. The authors rated the validity of studies using a standard checklist and calculated the pooled proportion of response to any treatment reported by at least three studies.
Results: All the studies that met inclusion criteria investigated pharmacological treatment. Most were open-label studies, and the authors found no double-blind randomized placebo-controlled trials. The overall response rate for all active treatments investigated was 52% (95% CI=42-62; N=381). Only lithium augmentation was assessed in more than two trials, and the response rate was 42% (95% CI=21-65; N=57). Only two studies included comparison groups receiving no additional treatment, and none of the participants in these groups responded. In single randomized studies, extended-release venlafaxine was more efficacious than paroxetine, lithium augmentation more than phenelzine, and selegiline more than placebo.
Conclusions: Half of the participants responded to pharmacological treatments, indicating the importance of managing treatment-refractory depression actively in older people. The only treatment for which there was replicated evidence was lithium augmentation. Double-blind randomized controlled trials for management of treatment-refractory depression in older people, encompassing pharmacological and nonpharmacological therapies and populations that reflect the levels of physical and cognitive impairment present in the general older population with depression, are needed.
Similar articles
-
Lithium augmentation compared with phenelzine in treatment-resistant depression in the elderly: an open, randomized, controlled trial.J Clin Psychiatry. 2007 Aug;68(8):1177-85. doi: 10.4088/jcp.v68n0803. J Clin Psychiatry. 2007. PMID: 17854241 Clinical Trial.
-
Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials.J Clin Psychiatry. 2011 Dec;72(12):1660-8. doi: 10.4088/JCP.10r06531. J Clin Psychiatry. 2011. PMID: 22244025
-
Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies.J Clin Psychopharmacol. 1999 Oct;19(5):427-34. doi: 10.1097/00004714-199910000-00006. J Clin Psychopharmacol. 1999. PMID: 10505584
-
Lithium augmentation therapy in refractory depression: clinical evidence and neurobiological mechanisms.Can J Psychiatry. 2003 Aug;48(7):440-8. doi: 10.1177/070674370304800703. Can J Psychiatry. 2003. PMID: 12971013 Review.
-
Lithium's emerging role in the treatment of refractory major depressive episodes: augmentation of antidepressants.Neuropsychobiology. 2010;62(1):36-42. doi: 10.1159/000314308. Epub 2010 May 7. Neuropsychobiology. 2010. PMID: 20453533 Review.
Cited by
-
[Lithium treatment for affective disorders in old age].Nervenarzt. 2024 Jan;95(1):41-45. doi: 10.1007/s00115-023-01601-5. Epub 2024 Jan 8. Nervenarzt. 2024. PMID: 38189940 Review. German.
-
Facts and myths about the use of lithium for bipolar disorder in routine clinical practice: an expert consensus paper.Ann Gen Psychiatry. 2023 Dec 6;22(1):50. doi: 10.1186/s12991-023-00481-y. Ann Gen Psychiatry. 2023. PMID: 38057894 Free PMC article. Review.
-
Three-Year Prognosis of Late-Life Depression in an Outpatient Geriatric Psychiatry Clinic: Medical Comorbidities Worsen Outcomes.Psychiatr Q. 2023 Dec;94(4):675-689. doi: 10.1007/s11126-023-10053-8. Epub 2023 Sep 30. Psychiatr Q. 2023. PMID: 37776466
-
Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions.World Psychiatry. 2023 Oct;22(3):394-412. doi: 10.1002/wps.21120. World Psychiatry. 2023. PMID: 37713549 Free PMC article.
-
A Review of Therapeutics for Treatment-Resistant Depression in the Older Adult.Drugs Aging. 2023 Sep;40(9):785-813. doi: 10.1007/s40266-023-01051-3. Epub 2023 Aug 18. Drugs Aging. 2023. PMID: 37596380 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous